Technical Analysis for NKTR - Nektar Therapeutics

Grade Last Price % Change Price Change
grade C 33.47 -3.32% -1.15
NKTR closed up 3.22 percent on Tuesday, June 25, 2019, on 89 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical NKTR trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish -4.32%
20 DMA Support Bullish -1.24%
Slingshot Bullish Bullish Swing Setup -3.99%
Upper Bollinger Band Walk Strength -3.99%
Shooting Star Candlestick Bearish -5.43%
Lizard Bearish Bearish Day Trade Setup -5.43%
Stochastic Reached Overbought Strength -5.43%
Upper Bollinger Band Walk Strength -5.43%
BB Squeeze Ended Range Expansion -5.43%
Overbought Stochastic Strength -5.43%

Older signals for NKTR ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist that is in Phase 3 clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase 2 clinical trail to treat gram-negative pneumonias; NKTR-181, a mu-opioid analgesic molecule, which is in Phase 2 clinical trail for chronic pain; and NKTR-192 that is in Phase 1 to treat acute pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase 3 clinical trial for the treatment of metastatic breast cancer; in Phase 2 clinical trail for ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 for the treatment of chronic pain; NKTR-171 to treat neuropathic pain; and NKTR-214, a cytokine immunostimulatory therapy for the treatment of oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. Further, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, MAP Pharmaceuticals, Merck, Pfizer, Roche, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.
Chemistry Biotechnology Biopharmaceutical Manufacturing Pharmaceutical Pain Drugs Pharmacology Ovarian Cancer Chronic Pain Morphinans Anti Infectives Metastatic Breast Cancer Opioid Antagonists Pegylation Treatment Of Metastatic Breast Cancer Diols Metastatic Colorectal Cancer Opioid Induced Constipation
Is NKTR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 69.76
52 Week Low 29.22
Average Volume 1,590,402
200-Day Moving Average 39.6091
50-Day Moving Average 33.0201
20-Day Moving Average 33.6685
10-Day Moving Average 34.44
Average True Range 1.3487
ADX 16.2
+DI 25.2877
-DI 19.3874
Chandelier Exit (Long, 3 ATRs ) 32.5639
Chandelier Exit (Short, 3 ATRs ) 34.8461
Upper Bollinger Band 35.8012
Lower Bollinger Band 31.5358
Percent B (%b) 0.81
BandWidth 12.668815
MACD Line 0.475
MACD Signal Line 0.34
MACD Histogram 0.1349
Fundamentals Value
Market Cap 5.47 Billion
Num Shares 156 Million
EPS -1.40
Price-to-Earnings (P/E) Ratio -24.99
Price-to-Sales 27.79
Price-to-Book 1075.45
PEG Ratio 3.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 37.96
Resistance 3 (R3) 37.82 36.69 37.47
Resistance 2 (R2) 36.69 35.93 36.76 37.30
Resistance 1 (R1) 35.83 35.46 36.26 35.97 37.14
Pivot Point 34.70 34.70 34.91 34.77 34.70
Support 1 (S1) 33.84 33.94 34.27 33.99 32.82
Support 2 (S2) 32.71 33.47 32.78 32.66
Support 3 (S3) 31.85 32.71 32.49
Support 4 (S4) 32.00